drugset / Trial / NCT00860158
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.
Timeline
- Start
- 2009-03
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | 7.5 mg | Subcutaneous |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |